INTRODUCTION
Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury characterized by a hypoxemic respiratory failure following a disruption of the endothelial-epithelial barrier, alveolar damage and pulmonary edema (1, 2) . In spite of significant advances in critical care, antibiotics, and lung ventilation strategies, effective therapeutic interventions to diminish the severity of lung injury and mortality among ARDS are not available (3) (4) (5) . Neutrophils are the first line of innate immune response producing anti-bacterial peptides, reactive oxygen species, cytokines, and other inflammatory mediators (6) . Neutrophils are also able to release extracellular traps (NETs), a unique mechanism of DNA deployment into the extracellular milieu (7, 8) . Although these functions are important to target microbial agents, neutrophil exaggerated and prolonged activation could contribute to the development of acute lung injury (ALI) (9) (10) (11) . In particular, prolonged life span of neutrophils occurs during ARDS and several studies have shown a deleterious impact associated with neutrophil delayed apoptosis (9, (12) (13) (14) . Similarly to substantial production of inflammatory mediators, neutrophil-driven excessive NETs formation can worsen inflammation, in particular in sterile inflammatory conditions (15) (16) (17) . Therefore, time dependent neutralization of apoptotic cells, especially apoptotic neutrophils and clearance of NETs appeared to be important steps in the resolution phase and recovery from lung injury since an effective removal of dying cells known as efferocytosis plays a crucial role in the maintenance of tissue homeostasis (18) .
Macrophage phagocytic function is typically associated with engulfment of dying cells, however less is known about the mechanisms involving NET clearance (19) (20) (21) .
Besides recently described benefit of DNAse I in experimental sepsis, the role of macrophages in the clearance of NETs, including in conditions associated with development and resolution from ARDS are not determined (22) . AMP-activated protein kinase (AMPK) is a serine-threonin protein kinase that functions as crucial metabolic sensor and regulates cellular energy production and expenditure (23) . More recent studies indicate that AMPK activation has also a potent anti-inflammatory effect. In addition, AMPK activation can stimulate macrophage efferocytosis, along with neutrophil and macrophage capacity to ingest bacteria (24, 25) . However, inflammatory conditions are accompanied with a reduced activity of AMPK in macrophages, neutrophils and in lung tissue. Restoration of AMPK activity could be an interesting approach to increase efferocytosis and likely to decrease inflammatory-lung injury in human, as already reported in mouse models of ALI (25, 26) . Moreover, High-mobility group box (HMGB)-1, an alarmin that may promote inflammation, has been involved in the development of severe ARDS and has been shown to inhibit efferocytosis (27) (28) (29) .
We thus designed the present study to investigate the ability of regulation of lung inflammation by neutrophils and macrophages in patients with ARDS. Our objectives were first to evaluate the survival of neutrophils and their ability to produce NETs.
Then, we studied macrophage capacity to engulf apoptotic cells and NETs. Finally, two potential therapeutic targets, AMPK and HMGB1, were considered to restore efferocytosis and NET clearance, and thus to reduce persistent inflammation and decrease lung injury in patients with ARDS.
MATERIAL AND METHODS

Patients
This study was conducted in the medical intensive care unit (ICU) of Rennes University Hospital. The study protocol was approved by local ethic committee (n°14.38). Because of the observational nature of the study, a non-opposition form was provided to families and patients. Patients with Berlin criteria for ARDS were consecutively enrolled and compared with patients who underwent bronchoscopy in the department of pulmonary medicine with normal BAL (control patients) (30) .
Bronchoalveolar lavages (BAL)
BAL were performed within two days following initiation of mechanical ventilation in ARDS patients, or in an outpatient setting for control participants. BAL fluid was obtained by centrifugation and cell population differentials were determined on cytospin slides after May-Grunwald Giemsa coloration.
Cytokine quantification
Interleukine (IL)-6, IL-8, chemokine ligand 2 (CCL2), C-X-C motif chemokine 10 (CXCL10), plasminogen activator inhibitor-1 (PAI-1) (R&D System, Abingdon, UK), and HMGB-1 (IBL International GmbH, Hamburg, Germany), were quantified in BAL fluids by ELISA.
Cell isolation and culture
Human primary bronchial epithelial cells (BEC) were obtained from lung donor trachea or bronchi of the Cohort Of Lung Transplantation (COLT, NCT00980967).
Tissues were dissociated overnight at 4°C with collagenase in HEPES-buffered RPMI medium (Sigma-Aldrich, St Louis, MO, USA). BEC were cultured in cnT17 medium (CELLnTEC Advanced Cell systems AG, Bern, Switzerland) containing penicillin and streptomycin, on human type IV collagen (Sigma-Aldrich) coated plates.
Blood samples were obtained from ARDS patients within hours following BAL, or from healthy donors. Neutrophils were purified as previously described (31) .
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient (Eurobio, Courtaboeuf, France). PBMCs were incubated in RPMI 1640 containing 7% fetal calf serum (FCS) and 1% penicillin-streptomycin at 37°C. After 1 hour, non-adherent cells were removed by washing with complete medium. Human monocyte-derived macrophages (HMDMs) were then derived from adherent monocytes by culture with 20 ng/mL macrophage-colony stimulating factor (M-CSF, R&D Systems, Abingdon, UK) for 5 days. Purity of HMDMs was >80% and evaluated by flow cytometry. 
Apoptosis and necrosis Assay
NET release quantification
Neutrophils were incubated for 30 minutes in 50% RPMI-7% FCS and 50% BAL fluid or saline. When indicated, BAL fluids were before neutralized with an anti-HMGB1 (IBL International GmbH, Hamburg, Germany) mAb or isotype for 2 hours. 
NET isolation and phagocytosis by macrophages
Neutrophils from ARDS patients or healthy donors were incubated in RPMI with 25 nmol/L PMA for 2 hours at 37°C. After centrifugation, NETs were quantified in the supernatant by measuring fluorescence using Sytox blue (5 µmol/L). HMDMs were allowed to attach in Corning 96-well black plates for 3 hours in 50% RPMI-7% FCS and 50% BAL fluid or saline, then Sytox blue-labelled purified NETs were added.
After incubation for 2 hours at 37°C, HMDMs were washed and NET phagocytosis was assessed by fluorescence quantification. NET engulfment ratio was determined as the ratio of fluorescence of HMDMs having phagocytized NET to the fluorescence of HMDMs alone. When indicated, HMDMs were incubated with an anti-HMGB1 neutralizing antibody or isotype, or with metformin (500 µmol/L, Sigma-Aldrich, St Louis, MO) for 2.5 hours.
Immunofluorescence stainings
For NET imaging, purified neutrophils were immobilized on slides coated with poly-Dlysine (Sigma-Aldrich, St Louis, MO), and incubated with 50% RPMI-7% FCS and 50% BAL fluid from control or ARDS patients for 3 hours. Cells were fixed with 4% paraformaldehyde (PFA, Antigenfix Diapath, Martingo, Italy). Coverslips were mounted with mowiol including Sytox blue (5 µmol/L).
For phagocytosis imaging, HMDMs were derived from monocytes on chamber coverslips with M-CSF (20ng/mL) for 5 days. HMDMs were then incubated for 3 hours with RPMI containing neutrophil-isolated NETs or not. Cells were fixed with 4% PFA and labelled with anti-neutrophil elastase mAb (Dako, Carpinteria, CA) followed For all imaging, slides were examined with a SP5 confocal microscope (Leica Microsystem, Wetzlar, Germany). Digital images were processed using ImageJ software.
Western blot
(Phospho)-AMPK Western blotting was performed using mouse anti-AMPKα or rabbit anti-phospho-AMPKα antibodies (Cell Signaling Technology, Danvers, MA), followed by HRP-conjugated anti mouse or anti rabbit secondary IgG (Santa Cruz Biotechnology, Santa Cruz, CA). Actin was blotted as loading control, using mouse anti-α-actin (Sigma-Aldrich, St Louis, MO) and HRP-conjugated anti mouse secondary IgG. Blots were quantified by using ImageJ software (National Institute of Health, Bethesda, MD).
Statistical analysis
Quantitative variables are expressed as mean ±SD or median (interquartile range, IQR) when indicated, and qualitative variables as number (percentage). Continuous variables were compared using the nonparametric Mann-Whitney U test or Wilcoxon test for matched pairs as appropriate. Analyses were performed with GraphPad Prism 6.2 (GraphPad Software, La Jolla, CA).
RESULTS
NET formation in ARDS patients may contribute to lung injury.
Among ARDS BAL leukocytes, neutrophils were the predominant cell population whereas the majority of BAL leukocytes in controls are macrophages (Supplemental Figures 1AB) . Specific descriptions of ARDS patients and control subjects are provided in Table 1 . Figure 1C ) (13, 32) . We also found significant increased levels of PAI-1, implicated in down regulating efferocytosis in animal models of acute lung injury (ALI) ( Figure 1A ) (33) . Because HMGB1 has been shown to promote NET release in experimental ALI, we also examined this possibility in ARDS patients (34) . We found that HMGB1 was significantly increased in BAL fluid of ARDS patients vs controls ( Figure 1A ).
Subsequent analysis revealed substantial amounts of cell free DNA in BAL fluid of ARDS patients, suggesting that HMGB1 accumulation is accompanied by an enhanced NETosis ( Figure 1B ). Furthermore, BAL fluids from ARDS patients have been found to induce lung epithelial cell injury which could be related to NETs (Figure   1 C-F).
Neutrophils of ARDS patients enhanced capacity to produce NETs.
The cell-free DNA found in BAL fluids could be a result of DNA release from necrotic cell death. However, we found that neutrophils in BALs of ARDS patients had relatively low apoptotic index (data not shown) but also that circulating neutrophils of ARDS patients presented an increased capacity to produce NETs ex vivo, as compared to healthy donors (Figure 2A 
Neutrophils of ARDS patients show increased viability
In inflammatory conditions, like in ARDS, neutrophils are known to acquire a prolonged viability. To determine neutrophil viability, apoptotic indices were measured after 24 hours of neutrophil culture. The amounts of apoptotic neutrophils were significantly lower in circulating neutrophils from ARDS patients compared to healthy donors. This result confirmed that viability of neutrophils is increased in ARDS patients ( Figure 3A) . In subsequent experiments, we examined the effect of BAL fluids on neutrophil viability. As shown in Figure 3C , BAL fluids from ARDS, unlike from control patients, increased the viability of healthy donor circulating neutrophils. Apoptotic percentage was even further decreased after exposure of ARDS circulating neutrophils to ARDS BAL fluids ( Figure 3D ). However, to ensure that specific constituent(s) of BAL fluids in ARDS patients increased neutrophil viability, we also explored necrosis rate and found a trend toward in diminished neutrophil necrosis when exposed to BAL fluids from ARDS patients ( Figure 3E ).
Monocyte-derived macrophages from ARDS patients have diminished ability to
phagocyte NETs and apoptotic neutrophils.
The ability of macrophages to neutralize apoptotic neutrophils plays a central role in termination and resolution of inflammatory conditions. Recent studies also indicate that macrophages are involved in clearance of NETs (20, 35) . As shown in Figure 4E ). Even further reduction in phagocytic indices were found in ARDS HMDMs treated with ARDS BAL fluids ( Figure 4F ). In contrast, BAL fluids of control patients had no impact on efferocytosis ( Figure 4E -F) .. This finding also suggests that reduced efferocytosis was mediated by soluble components in lung fluid of ARDS patients.
The effects of AMPK and HMGB1 on efferocytosis and NET clearance.
To determine factor(s) that are affecting NETosis, efferocytosis and NET engulfment, we first examined the impact of HMGB1( Figure 5A ). We did not observe any significant effect of HMGB1-neutralizing antibody on NET formation ( Figure 5B) .
In contrast, we found that an anti-HMGB1 antibody increased the clearance of apoptotic neutrophils by ARDS HMDMs ( Figure 5C ) and had no effect on NET uptake ( Figures 5D) . The ability of HMGB1 to affect efferocytosis is consistent with previous studies in a murine models of inflammatory organ injury, in particular linking HMGB1 release in extracellular mileu with diminished clearance of apoptotic cells.
Besides adverse effects mediated by extracellular HMGB1, inflammatory conditions
are associated with metabolic reprogramming of immune and parenchymal cells which are associated with diminished activity of AMPK in macrophages (36) . Notably, AMPK activators, including metformin have been shown to promot efferocytosis and also to reduce the severity of ALI. Thus, we examined if AMPK activation can also recover phagocytic capacity of HMDMs from ARDS patients. As shown in Figure 5F , AMPK activation, i.e. phosphorylation of Thr172-AMPK was significantly diminished in HMDMs treated with BAL fluid of ARDS patients. Moreover, we indicate that culture of ARDS HMDMs with metformin restored AMPK activation ( Figure 5G ). This activation was associated with a significant increased in uptake of apoptotic neutrophils and NETs ( Figure 5H and I).
DISCUSSION
Our study reveals major findings that could enhance or sustain lung inflammation during ARDS. Firstly, although neutrophil lifespan is significantly increased, intraalveolar neutrophils are releasing NETs through a pathway termed vital NETosis and BAL fluid of ARDS patients can increase the release of NETs which could induce lung injury. Secondly, in ARDS conditions, ability of macrophages to engulf NETs and apoptotic cells is significantly decreased. We also found that blocking HMGB1 and activating AMPK could enhance clearance of NETs and apoptotic cells.
Clinical and histological studies have suggested that the severity and outcome of ARDS were associated with the inflammatory process reflected in bronchoalveolar fluid (13) . A large number of clinical and animal studies brought evidences that neutrophils have a direct influence on the onset and the persistence of ARDS. For instance, Steinberg et al. found that alveolar macrophages increased in ARDS survivors compared to non-survivors reaching the conclusions that sustained alveolar inflammation was associated with high mortality (12) . Among factors which could sustain inflammatory conditions, increased NETosis, decreased ability of macrophages to engulf apoptotic cells and NETs, appear to be critical.
We found that neutrophils could produce large amounts of NETs, spontaneously or when exposed to ARDS BAL fluids. NETs are composed of decondensed chromatin fibers coated with antimicrobial proteins. NETosis could require membrane rupture and the loss of neutrophil functions (so called suicidal NETosis) (17 (15, 39) . Two mechanisms have been described in NET clearance: DNase I-dependent digestion and phagocytosis by macrophages which has been found diminished in our study (17) . We also We found that BAL fluid from ARDS patients could induce a decrease in efferocytosis in both healthy and ARDS macrophages, allowing therapeutic intervention to enhance efferocytosis and engulfment of NETs. Along these lines, AMPK pathway appears to be a potential therapeutic target. We found in our study that ability of macrophages to activate AMPK was decreased in inflammatory conditions which could be associated to a defect in efferocytosis activity (24) . Of note, the ability of AMPK activation to enhance phagocytosis appears to be related to interaction with cytoskeletal organization, (24) . Lastly, we found that inhibition of HMGB1 could increase efferocytosis as already reported in animal model of lung injury. HMGB1, originally described as a nuclear non-histone DNA-binding protein, has subsequently been shown to be an alarmin involved in the inflammatory response playing a critical role in the recruitment of neutrophils, lung injury and suppressing bacterial clearance in the lung (31, 34, 42) . It is worth noting that metformin has been found to bind and inhibit the action of HMGB1, suggesting that the effects of metformin could be similar to those of HMGB1 inhibition (43) High levels of HMGB1 in BAL fluid from ARDS patients can decrease efferocytosis, suggesting that inhibition of HMGB1 as activation of AMPK, could be of interest to restore efferocytosisdiminish lung injuries, and ultimately improve lung function after ICU discharge.
CONCLUSION
Altogether, our results show that efferocytosis and NET engulfment which could contribute to the persistence of lung inflammation are diminished during ARDS.
Restoration of AMPK activation with metformin and specific inhibition of HMGB1
appear to be promising targets to decrease lung inflammation, and to limit alveolar damage and progression to lung fibrosis in patients with ARDS. 
